Annual Report

Overview

The report describes the company's evolution into an innovation-driven life sciences organization, supported by continued research, new products and global pharmaceutical operations. Consolidated revenue from operations increased to ₹152,652 million in FY22 from ₹144,035 million in the prior year. The company also reports a broad CSR programme focused on health, education and research, including free medical services through Zydus Medical College and Hospital at Dahod. Its people initiatives covered training, skill development and employee support across the group.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2021-2022
Period: 1 April 2021 – 31 March 2022
Publication date: 20 May 2022
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services